DrugPatentWatch Database Preview
Sb Pharmco Company Profile
» See Plans and Pricing
What is the competitive landscape for SB PHARMCO, and what generic alternatives to SB PHARMCO drugs are available?
SB PHARMCO has three approved drugs.
There are two US patents protecting SB PHARMCO drugs.
There are one hundred and ten patent family members on SB PHARMCO drugs in forty-six countries and fifty-six supplementary protection certificates in fourteen countries.
Drugs and US Patents for Sb Pharmco
Expired US Patents for Sb Pharmco
Paragraph IV (Patent) Challenges for SB PHARMCO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 1 mg/4 mg, 2 mg/4 mg and 4 mg/4 mg | ➤ Subscribe | 2006-12-22 |
➤ Subscribe | Tablets | 1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg and 4 mg/ 1000 mg | ➤ Subscribe | 2004-10-22 |
➤ Subscribe | Tablets | 8 mg/2 mg and 8 mg/4 mg | ➤ Subscribe | 2008-05-30 |
International Patents for Sb Pharmco Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20010774 | Start Trial |
Malaysia | 125516 | Start Trial |
Australia | 2755102 | Start Trial |
African Regional IP Organization (ARIPO) | 1389 | Start Trial |
Yugoslavia | 38802 | Start Trial |
Bulgaria | 65616 | Start Trial |
European Patent Office | 1231918 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sb Pharmco Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1261586 | C300524 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION: |
0658161 | SPC/GB01/003 | United Kingdom | Start Trial | PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
2498758 | LUC00152 | Luxembourg | Start Trial | PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113 |
0658161 | 39/2000 | Austria | Start Trial | PRODUCT NAME: ROSIGLITAZONE MALEAT; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929 |
1412357 | DO 77; 5006-2008 | Slovakia | Start Trial | PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
0306228 | 38/2000 | Austria | Start Trial | PRODUCT NAME: ROSIGLITAZONE; NAT. REGISTRATION NO/DATE: EU/1/00/137/001 - EU/1/00/137/012 20000711; FIRST REGISTRATION: LI 55176 19990929 |
2498758 | CA 2020 00017 | Denmark | Start Trial | PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.